Form 4: Mirum Pharmaceuticals CEO Christopher Peetz Reports Stock Transactions
SEC Form 4 Filing
Christopher Peetz, CEO of Mirum Pharmaceuticals, reports the acquisition and disposal of company stock, including the vesting of restricted stock units and sales to cover tax obligations.
Summary
- On January 23, 2025, Christopher Peetz, the CEO of Mirum Pharmaceuticals, exercised restricted stock units to acquire 12,500 shares of common stock.
- On January 24, 2025, Peetz sold 6,837 shares of common stock at a price of $47.9243 per share.
- Following these transactions, Peetz directly owns 125,022 shares and indirectly owns 208,570 shares through The Peetz Family Trust.
- The sales were made to cover tax withholding obligations associated with the vesting of restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by the CEO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors regarding the buying and selling activities of company executives and directors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's holdings, but the sales are primarily for tax obligations.
Key Dates
| Date | Description |
|---|---|
| 01/23/2024 | Vesting Commencement Date for restricted stock units |
| 01/23/2025 | Exercise of restricted stock units for 12,500 shares |
| 01/24/2025 | Sale of 6,837 shares at $47.9243 per share |
| 01/27/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.